6 results about "Targeted disruption" patented technology

Provided herein are shaped-charges having curved walls to provide better controllable and improved liquid jet parameters. The shaped-charge comprises a container having a plurality of curved walls for containing a liquid. One or more explosive charges are immersed in the liquid and a detonator channel positioned through the container wall to controllably detonate the one or more explosive charges and from a wedge-shaped liquid jet. Multipoint initiation is achieved using a number of initiation points; a location of one or more initiation contact points with the geometrically-shaped explosive charges; and / or an initiation timing of each of the initiation contact points, including simultaneous initiation or a sequence of initiations. Also provided are related methods of forming liquid jets and attendant applications, including target disruption.

This invention discloses a method for pretreating camellia seeds using low-temperature plasma, relating to the field of bioengineering technology. The method involves discharging the entire surface of the camellia seed using DBD, JET, DF, or RF at atmospheric pressure, preferably DBD 120kV×1min or RF 3m / min at a distance of 0-3mm for 20 passes. This achieves microporousization of the seed coat and targeted disruption of the cell wall to promote mass transfer. The treatment reduces lipase and lipoxygenase activities by approximately 31.72% and 35.69% (or 29.54%), respectively, and significantly enhances the antioxidant capacity of total phenols and DPPH / ABTS / FRAP in the methanol extract (up to 1.58 times the total phenols). This method simultaneously promotes the release of active ingredients, inhibits lipid oxidation, and improves oil yield and quality under low-temperature, non-thermal conditions, making it suitable for continuous industrial applications.

The present invention discloses a sgRNA for targeted disruption of Aqp1 mRNA, its vector, and its application, capable of significantly downregulating Aqp1 mRNA levels. Upon delivery to cells via the vector, the sgRNA can target and disrupt Aqp1 mRNA, reducing Aqp1 mRNA levels. These sgRNAs can be used to treat diseases where downregulating Aqp1 expression is beneficial, including but not limited to diseases associated with Aqp1 overexpression, including cancer and glaucoma.

Provided herein are methods and systems for targeted gene disruption (knock-out, missense mutation) and targeted gene knock-in in mammalian cells using base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Also provided herein are universally acceptable genetically engineered cells comprising targeted disruptions in immunotherapy-related genes and comprising a CAR / TCR for therapeutic applications.

The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for compositions and methods that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. For example, disclosed herein is a system for inducing targeted disruption of endogenous genes in a eukaryotic cell, the system comprising: an extracellular Cas9 / RNA complex; cell-free and a buffer; wherein the extracellular Cas9 / RNA complex comprises: a recombinant Cas9; and a guide RNA having a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA); wherein the extracellular Cas9 / RNA complex is disposed in the cell-free buffer and wherein the extracellular Cas9 / RNA complex is complexed prior to being introduced into the eukaryotic cell; and wherein the Cas9 / RNA complex functions as an endonuclease that induces targeted disruption of the target DNA upon introduction into the eukaryotic cell.

Provided herein are methods and systems for targeted gene disruption (knock-out, missense mutation) and targeted gene knock-in in mammalian cells using base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Also provided herein are universally acceptable genetically engineered cells comprising targeted disruptions in immunotherapy-related genes and comprising a CAR / TCR for therapeutic applications.